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codynamic and virulence expression. Opportunities for combining 
convennonal approaches with biological response modification has 
been intensely hstrating and in part reflects our inabihty to cre- 
ate sensitive, reproducible and ckscriminatory human test models. 
However, the future approaches to the management of mfection re- 
main exciting and will clearly see progress on many hnts .  While 
chemotherapeutic intervention is likely to remain for the immediate 
future, opportunities for impacting of microbial virulence and host 
response are likely to emerge. 
(s381 Meta-analysis: A Useful Tool for Evaluating Data 
in Abdominal Infection 
J.S. Solomkin. University of C i M n m t i  College ofhfedicine, Cinn'nmti, 
Ohio, U S A  
Objective: To explore the utility of meta-analysis in in- 
tra-abdominal mfection. 
Methods: A meta-analysis of eight pre-marketing multicentre 
randomised clinical a d s  comparing treatment with meropenem 1 
g 8-hourly to over regimens, including imipenem/cilastatin, cefo- 
taxime plus metronidazole, and tobratnycin plus dindamycin. From 
1335 patients recruited into the studies, a total of 711 patients (355 
patients treated with meropenem and 356 with COmparatON) were 
both clinically and bacteriologically evaluable and included in the 
analysis. Logistic regression was used to demonstrate normality of 
the included data sets. 
Results: The overall clinical response rate was s& for the 
meropenem p u p  (336/355, 94.6%) and the comparator group 
(329/356, 92.4%). Response rates for the individual comparators 
were also similar. The overall odds ratio for treatment failure (es- 
timated from the odds ratios for all studies combined) was 0.76 
(95% confidence interval: 0.45, 1.26). A logistic regression analysis 
to identfy correlates of failure showed that length of hospital ad- 
mission, &se peritonitis and APACHE I1 score were sipficant 
contributors (overall model xz = 54.941, p < 0.0001). 
Conclusions: The data presented in this analysis support the opti- 
misation of carbapenem dosing for the treatment of intra-abdominal 
infection, and indicate that meropenem 1 g 8-hourly is as effec- 
tive as the standard comparators used in these mals. We believe that 
meta-analysis provides an important tool for examining clinical trials 
data in the area of intra-abdominal mfections. 
The Impact of Antibiotic Treatment on Endotoxin 
Release 
M.H. Miller. Albany Medical College, Albany, New Yo&, USA 
Recent in vitro and in yivo studies have explored the possibility that 
the extent and rate of bacterial eradication may not be the fac- 
tor whch best correlates with outcome in patients with selected 
Gram-negative infections. For B-lactams, a possible relationship has 
been proposed between PBP binding aEinity, relative endotoxin 
(LPS) release and outcome. In v i m  data suggest Werences in LPS 
release in E. coli and I? amginosa exposed to B-lactams with dif- 
ferent PBP &ty. However, the rate and extent of LPS release is 
concentration-dependent and best demonstrated using experimen- 
tal conditions whch may not be clitllcal relevant. Our studies with 
I? aeruginosa show a dissociation between LPS and murein release 
which, dong with morphological studies, suggest that both cell en- 
velope bruption and changes in biomass contribute to these dif- 
ferences. The potentla importance of dissmihities in LPS release 
is further confounded by the fact that aminoglycosides, often used 
in Combination with B-lacrams, show dose-dependent LPS bin- 
in vitro and decrease LPS effects in mice. W e  studies in rodents 
treated with fi-lactams also suggest that PBP bindmg correlates with 
LPS release and outcome, the doses used often result in pharmaco- 
dynamic profiles whch differ from those in man, and amino$yco- 
sides plus B-lactams significantly improve suMval when compared 
with monotherapy. Moreover, data in humans suggesting differences 
among B-lactams that relate to ditferences in PBP binding and en- 
dotoxin release are limited, and the clinical consequences are un- 
certain. Important factors in designing human stumes to determine 
the relevance of drug-induced LPS release include: in viho studies 
characterising the precise mechanisms of B-lactam-induced LPS re- 
lease and aminoglycoside binding; 4 outcome data using doses 
based upon pharmacodynamic principles; and careful consideration 
of comorbid conditions. Until such clinical data are available, antibi- 
otic choice should be based on eficacy rather than the theoretical 
consequences of LPS release. 
(s40( Differentiating Treatment Options for Serious 
Infections 
S.R. Norrby Department oflnfecous Disemer, Lund University 
Hospital, Land, Sweden 
During the last 15 years there has been a gradual change in the 
choice of antibiotics for the empirical treatment of life-threatening 
bacterial infections. The use of B-lactadaminoglycoside combina- 
tions has been replaced by third- generation cephalosporins with 
or without antibiotics with anti-anaerobic activity. Imipenem/cilas- 
tadn, the first carbapenem to be developed, has been the an- 
tibiotic of choice in some situations, particularly when anaerobic 
aetiology has been suspected. The fluoroquinolones have gained 
very h t e d  clinical use, often due to their poor activity against 
Gram-positive bacteria and against anaerobes. The sometimes in- 
discriminate use of third-generation cephalosporins has resulted in 
well-defined problems; namely, abundant resistance in Enterobaaer 
spp due to class I cephalosporinases and an increasing incidence of 
infections caused by members of the Enterobacteriaceae harbour- 
ing extended-spectrum B-lactamases. In addition, there are indica- 
tions that overuse of third-generation cephalosporins might favour 
the selection of Clostridium d@le, methicillin-resistant Stap~lococ- 
c i u  aureus and vancomycin-resistant enterococci. In the carbapenem 
group, imipenem/cilastatin has been joined by meropenem. The ad- 
vantages of meropenem over imipenem/cilastatin include: (i) better 
Gram-negative activity, particularly against Pseudomo~c ueruginosa, 
Haemophilus injuenzae, and the Enterobacteriaceae including hrm 
spp, Provider& spp and hforgunelh morganii; (ii) better solubhty al- 
lowing the use of intravenous bolus injections; (iii) a low incidence 
of nausea; and (iv) a low potentla for neurotoxicity, allowing the 
use of high doses and offering the possibility of using meropenem 
in patients win CNS infections. Meropenem therefore offers a novel 
option for the empirical therapy of Me-threatening infections, such 
as nosocomial pneumonia, and intra-abdominal, gynaecological and 
CNS infections. 
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Prevalence of local aminoglycoside resistance 
mechanisms and their impact on the 
management of infectious diseases 
G. Miller. Shering-Plough Research Institute, Kcnilworth, v, USA 
The prevalence of aminoglycoside resistance mechanisms in dif.- 
Bacterial mechanisms for  evading cellular host defences 11 
ferent European and Latin American countries has been deter- 
mined in surveys carried out between 1989 and 1997. In some 
countries - Germany, UK, Italy, Spain, Denmark and Finland - 
aminoglycoside resistance in Enterobacteriaceae is predominantly 
caused by gentamicin-modtfymg enzymes (AAC(3)-1, AAC(S)-II, 
and/or ANT(2”)-I). However, in other countries - Belgium, 
France, Greece, Portugal, Turkey, South Africa, Argentina, Chile 
and Mexico - aminoglycoside resistance is most often caused by an 
amikacin-modifymg enzyme (AAC(6‘)-I) either alone or in combi- 
nation with the above-mentioned gentamicin-mo-g enzymes. 
A correlation between the types of enzymes observed and amino- 
glycoside usage in these countries has been suggested and will be 
discussed. 
In the treatment of mfections caused by resistant organism, a 
kequent problem in many intensive care units, the most ke ly  
mechanism of resistance to aminoglycosides should play a role in 
the empiric choice of antibiotics. In those hospitals where gentam- 
icin-modifymg enzymes predominate, n e h c i n  and amikacin may 
still be effective choices. Where ACC(6’)-I occurs alone, gentamicin 
may s t i l l  be useful. However, in countries where combinations of 
resistance mechanism occur, only isepamicin retains good in vitro 
activity and should be considered as a first choice in situations where 
aminoglycoside resistance is high. 
How do pharmacokinetics influence the choice of 
aminoglycoside in the critically 111 patient? 
E Scaghone. Department of Phamacology, University of Milan, Milan, 
Italy 
Aminoglycosides remain a mainstay of treatment for serious 
Gram-negative mfections. 
Following intramuscular administration, aminoglycosides are 
completely absorbed; they are not metabolized and any drug sub- 
stance in the plasma and urine is unchanged drug. Anminoglycosides 
are completely elmhated via the renal route. Doses should there- 
fore be adjusted in patients with renal insufficiency according to the 
extent of renal impairment. 
The area under the plasma concentration curve (AUC) is propor- 
tional to the dose of aminoglycoside administered while dearance, 
volume of distribution at steady state and half-life are independent of 
dose. After intravenous dosing, the aminoglycoside plasma concen- 
tration curve can be best characterized by a m-exponential curve. 
The first half-life represents the distribution phase, the second repre- 
sents the elimination phase, while the g-phase represents the return 
of the drug to the plasma &om deep compartments (i.e. binding in 
renal tissue). 
Isepamicin is a new aminoglycoside which has activity against 
many bacteria resistant to other aminoglycosides. The pharmacoki- 
netics of isepamicin are uncomplicated and generally s d a r  to those 
of other aminoglycosides, although evidence suggests that it may 
have hgher peak levels and less tissue accumulation. The g-phase 
is 34 hours while that of gentamicin and tobramycin is 94 and 96 
hours, respectively. Decreased tissue accumulation, implied h m  
these pharmacokinetic data, could be clinically relevant in term of 
reduced ototoxicity and renal toxicity, especially in compromised 
patients. 
The Evolution of Dosing Schedules in 
Aminoglycoside Therapy 
P. Tulkens. B 
No abstract available. 
The Rationale for and Use of Aminoglycosides in 
Combination Therapy 
J. Chow. USA 
No abstract available. 
Consensus on the clinical use of aminoglycosides 
-the Swiss Experience 
A.U. Gerber. Med. KZinik. Reg.spifal Biel-Bienne, Switzerland 
Background: Substand (up to five-fold), poorly understood varia- 
tions in the use and consumption of aminoglycosides (agly) has been 
observed among different Swiss hospitals of similar size and patient 
structure. 
Objective: Better understandmg of arguments for and against 
the use of agly for various indications. Swiss consensus for agly 
recommendations. 
Design: Consensus conference including experts h m  all Swiss 
university hospitals and representative county hospitals. 
Topics: Use and consumption of agly; role of agly and optimal 
schedule for various infections in different target patients; practice of 
monitoring. 
Conclusions: Agly are highly recommended (q8h) as part of the 
standard treatment of 1. endocarditis due to streptococci (MIC of 
peniG t 0.1 mg/l) or enterococci; 2. the initial 2-3 days of en- 
docarditis due to staphylococci; 3. the febrile neutropenic patient 
with sepsis; 4. exacerbations of bronchopulmonary infections in 
cystic fibrosis patients.Minor recommendatiom (OD regimen) are for: 
1. shortening the duration of antibiotic combination treatment of 
endocadtis due to streptococcus viridans (MID of peniG < 0.1 
mg/l); 2. combination treatment of the febrile neutropenic patient; 
3. the initial 2-3 days of Gram-negative sepsis (with shock); 3. sep- 
sis/meningitis in the newborn (q8h); 4. some infkquent infections 
such as tularemia, brucellosis, listeria, atypical mycobacteriosis. Mon- 
itoring of mugh lewls is highly recommended. In contrast, monitor- 
ing of peak levels is not needed in OD regimens in particular. 
Bacterial mechanisms for evading cellular 
host defences 
Cell Biology of Phagocytes: Lessons from 
Mycobacteria 
S .  Zimmerli. University Hospital, Zurich, Swi tzerhd  
Mycobacterium tuberculosis survives and replicates within mac- 
rophages but the mechanism whereby tubercle bacdb resist killing 
are incompletely understood. M. tuberculosis enter macrophages by 
receptor-mediated phagocytosis. A remarkable range of Merent 
macrophage receptors mediate phagocytosis and/or bindmg of M. 
tuberculosis: the complement receptors CR1, CR3 and CR4, the 
macrophage mannose receptor, the Fcg receptor, class A scavenger 
receptors, phagocyte CD14 molecules, and the surfactant protein A 
receptor of alveolar macrophages. The survival of certain intracel- 
lular pathogens like S. typhimurium, L. monocytogenes, and L. major 
within macrophages depends on selective use of a receptor that me- 
diates phagocytosis but not &g. In contrast, evidence h m  recep- 
tor blocking experiments suggests that the intracellular survival and 
replication of virulent M. tuberculosis is independent of the receptor 
that mediates phagocytosis. 
By selectively modulating the fusion-capacity of its phagosome 
M. tuberculosis seems to regulate its vacuole’s matuntion along the 
